Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 1645 publications.

Davis AE, Blake M, Lehoucq M, Brogan AJ, McDade C, Carlson KB, Lopman B, Buck PO. Estimates of the public health impact of norovirus vaccination for older adults in the United States. Poster to be given at the ISPOR 2025; May 16, 2025. Montréal, Canada.

La E, Singer D, Dubois de Gennes C, Graham J, Grace M, Poston S, Verelst F. Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination in US adults aged 60 years with cardiopulmonary disease. Poster to be given at the ISPOR 2025; May 15, 2025. Montreal, Canada.

Singer D, La E, Dubois de Gennes C, Graham J, Grace M, Biundo E, Poston S, Verelst F. Estimated public health impact of adjuvanted RSVPreF3 vaccination in US adults aged 18-49 years who are at increased risk for severe RSV disease. Poster to be given at the ISPOR 2025; May 15, 2025. Montreal, Canada.

Cha-Silva AS, Zhang KH, Graham C, Kurosky SK, Tran H, Law EH, Song EJ. A cost per responder analysis of ritlecitinib and baricitinib: assessing the impact of clinical efficacy and dosing variability on overall treatment costs of severe Alopecia Areata (AA). Poster to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Raza S, Heyes A, Leonard C, D'Souza V, Carney R, Mackie D, Gelinas D, Swijsen A. Analysis of the burden of illness, treatment, and health disparities in amyotrophic lateral sclerosis. Poster to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Loria-Rebolledo L, Watson V, Mohan D, Vass CM, Antunes M, Burns D, Ryan M. Over 30 years of discrete choice experiment studies in health economics: systematic review of current practice and reflections on evolving practice. Poster to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Marcano Belisario J, Lunan M, Hawe E, Farrelly G. Evaluation of machine learning assisted title and abstract screening in 5 clinical systematic literature reviews. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Marcano Belisario J, Hartley L, Phan NTN, Mugwagwa T, Tingir N. Economic systematic literature of nirmatrelvir+ritonavir for the treatment of patients with mild to moderate COVID-19. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Buck PM, Masaquel C. The most heavily managed drug categories on Part D formularies. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Earnshaw S, McDade C, Dodoo C, Huynh Z, Zhang K, Chang SN. Economic impact of multiplex point-of-care testing for chlamydia trachomatis, neisseria gonorrhoeae, and mycoplasma genitalium: development of a modeling framework. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Sauchelli S, Chicklis EK, Carty MK, Gnanasakthy A. Use of diaries to capture patient-reported outcomes in FDA new drug approvals (2019-2023). Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Dellon ES, Goodwin B, Liu E, de los Santos B, Korgaonkar S, Meyers J, Schaeffer-Koziol CR, Terreri B, Shah ED. Eosinophilic esophagitis-related healthcare resource utilization and associated costs for payers and patients: a retrospective cohort study of US health insurance claims data. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Clay B, Pop-Busui R, Januzzi JL, Neveux P, Zhang K, McDade C, Earnshaw S. Economic evaluation of NT-proBNP testing to facilitate prevention of heart failure in adults with type 2 diabetes. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Liang Y, Salomonsen R, Colosia A, Nelsen SH, Khan S, Sandelin M. Interventions to improve adherence and persistence to oral medication: a targeted literature review. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Chang M, Peters B, Ronquest N, Lucas A, Zhang Y, Simpson M, Shelley K. Assessing the budget impact and time savings of introducing nivolumab and hyaluronidase SC to patients receiving nivolumab IV across multiple indications on a US healthcare plan. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Ronquest N, Zhang Y, Mladsi D. Assessing the impact of the United States (US) Inflation Reduction Act (IRA) regulations on investment incentives for orphan disease drug development. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Hicks K, Xiao Z, Paret K, del Pilar Martin Matos M, Joshi K, Ghaswalla P. The annual economic burden of RSV in high-risk US adults aged 18-59: a modeling study. Poster to be given at the ISPOR 2025; May 13, 2025. Montréal, Canada.

Hicks K, Xiao Z, Paret K, del Pilar Martin Matos M, Joshi K, Ghaswalla P. The potential public health and economic benefit of an mRNA-based RSV vaccine, mRNA-1345, among high-risk adults aged 18-59 years in the US: a modeling study. Poster to be given at the ISPOR 2025; May 13, 2025. Montréal, Canada.

Nahas SJ, Zhao Y, Graham CN, Erbe A, Blumenfeld A. Comparative efficacy of AXS-07 vs. gepants for acute treatment of migraine: a network meta-analysis. Poster presented at the American Academy of Neurology (AAN) 2025 Annual Meeting; April 2025.

Rodriguez-Buritica DF, Dine J, Brown TM, Romano (DeMuro) C, Bratlee-Whitaker E, Ferrecchia I, Temkin G, Mora JJ, Babakhani RA, Ko JJ, Weinstein D. Qualitative interviews to support the development of a Patient-Reported Outcome (PRO) measure for glycogen storage disease type Ia. Poster presented at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting; March 18, 2025. Los Angeles, CA.

Singer D, La E, Dubois de Gennes C, Graham J, Grace M, Biundo E, Poston S, Verelst F. Modeled public health impact of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years at increased risk for severe RSV disease in the United States over 5 years. Poster presented at the 13th International Respiratory Syncytial Virus (RSV) Symposium; March 12, 2025. Iguazu Falls, Brazil.

Verelst F, La E, Singer D, Graham J, Grace M, Biundo E, Poston S. Modelled public health impact of adjuvanted RSVPreF3 vaccination in adults aged 60 years and older in the United States over 5 years. Poster presented at the 13th International Respiratory Syncytial Virus (RSV) Symposium; March 12, 2025. Iguazu Falls, Brazil.

Greenhawt M, Bansal P, Goodwin B, Korgaonkar S, Liu Y, Meyers J, Shah E, Terreri B, Dellon E, Schaeffer-Koziol C. High incidence and prevalence of eosinophilic esophagitis in the USA identified: an analysis of US health insurance claims data. Poster presented at the 2025 American Academy of Allergy Asthma & Immunology (AAAAI)/WAO Joint Congress; February 28, 2025. San Diego, CA.

Sutton Norman K, Zigler C, Brown M, Miller J, Bosworth H, Collyar D, Oakes M, Fowler V, Howard-Anderson J, Korn R, Ruffin F, Boucher H, Doemberg S, Reeve B, King H. Patient and clinician perspectives of care interactions for complicated urinary tract infections to inform implementation of patient-reported outcome measures: a qualitative descriptive study. Poster presented at the 17th Annual Conference on the Science of Dissemination and Implementation in Health; December 9, 2024. Arlington, VA.

Shadman M, Roeker L, Pinilla-Ibarz J, Srivastava B, Karve S, Krigsfeld GS, Franceschini E, Saifan C, Karanth S, Goyal RK, Rombi J, Stephens DM. Association between dose reduction and duration of therapy in patients receiving ibrutinib or acalabrutinib for chronic lymphocytic leukemia: a medical chart review study. Poster presented at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition; December 8, 2024. San Diego, California.

Kosa K, Vanegas A, Colavecchia C, Coulter J, Christopher SA, Fasano RM, Chou ST, Drachtman RA, Purdie DM, Baker CL, Meier ER. Qualitative interview study to characterize the treatment experiences of participants with sickle cell disease and assess perceptions of red blood cell transfusions. Poster presented at the American Society of Hematology (ASH) Annual Meeting & Exposition; December 8, 2024. San Diego, CA.

Benitez A, Andrews JS, Shah D, Mansfield C, Ross E, Rao S, Bussberg C, Galinksy J, Konermann-Bernhardt C, Lu M, Vass C. Caregiver preferences for dravet syndrome and lennox-gastaut syndrome treatments across the USA, UK, and Germany. Poster presented at the 2024 American Epilepsy Society (AES) Annual Meeting; December 7, 2024. Los Angeles, CA.

Krishnamurthy P, Houghton K, Lorenz N, Williams P, Currie L, Vigil CE, Ziba N, Bello F, Sieluk J, Strocchia M, Li Y, Kapp-Schwoerer S. Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia. Poster presented at the American Society of Hematology (ASH) Annual Meeting & Exposition; December 7, 2024. San Diego, CA.

Ahn MJ, Lin SH, Yang CT, Lee JB, Neal J, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nagar SP, Nasirova F, Kim YJ. Treatment (Tx) patterns and clinical outcomes in unresectable (UR) stg III EGFR-mutation positive (EGFRm) NSCLC treated with chemoradiotherapy (CRT): final analysis of a global real-world (rw) study. Poster presented at the European Society for Medical Oncology (ESMO) Asia Congress 2024; December 7, 2024. Singapore, China.

Rao S, McQuay L, Forns J, MacKay R, Aquilina T, Doshi D, Abler V, Anthony MS, Layton B. Mortality in patients with Parkinson's disease psychosis using pimavanserin versus other antipsychotics. Poster presented at the 2024 Parkinson Study Group (PSG) 33rd Annual Meeting; December 5, 2024. Nashville, TN. Previously presented at the Neuroscience Education Institute (NEI) Congress 2024.

Rao S, McQuay L, Forns J, MacKay R, Aquilina T, Doshi D, Abler V, Anthony MS, Layton B. Mortality in patients with Parkinson's disease psychosis using pimavanserin versus other antipsychotics. Poster presented at the Neuroscience Education Institute (NEI) Congress 2024; November 8, 2024. Colorado Springs, CO.

Clemmet T, Basarir H, Buompensiere MI, Chrastecka N, de Portu S, Dias RP, Dunne JL, del Pozo CH, Mader JK, Narendran P, Nicholls C, Alsaleh AJO, Piemonti L, Vercauteren J, Mahieu A. Economic evaluations of screening in pre-symptomatic type 1 diabetes (T1D): a systematic literature review. Poster presented at the Immunology of Diabetes (IDS) Congress 2024; November 4, 2024. Bruges, Belgium.

Yousif Z, Nangia A, Abeysinghe S, Jiang J, Sanchirico M, Fan T. Comparative efficacy of biologics for the induction of clinical remission and response in biologic-naïve patients with moderate-to-severe crohn's disease: outcomes from frequentist and bayesian network meta-analyses. Poster presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting 2024; October 29, 2024. Philadelphia, PA.

Rao S, McQuay L, Forns J, MacKay R, Aquilina T, Doshi D, Abler V, Anthony MS, Layton B. Comparing the mortality risk of patients on FDA-approved treatment for Parkinson's disease psychosis, pimavanserin, vs other antipsychotics. Poster presented at the 37th Annual Psych Congress; October 29, 2024. Boston, MA. Previously presented at the Neuroscience Education Institute (NEI) Congress 2024.

Dine J, Lee J, Shewale A, Stokes J, Basnyat B, Brown M, Greenblatt A, Shirneshan E. Understanding the early Alzheimer's disease experience: perspectives from patients and caregivers. Poster presented at the 17th Clinical Trials on Alzheimer's Disease (CTAD) 2024; October 29, 2024. Madrid, Spain.

Chapman KR, Guyot P, Ledanois O, Soliman M, Wang Z, Xu Y, Nangia A, Cheng W-H. Efficacy of dupilumab versus tezepelumab in asthma patients: matching-adjusted indirect comparison of long-term extension trials. Poster presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Annual Scientific Meeting; October 25, 2024. Boston, MA.

Broughton EI, Bektas M, Colosia A, Fernandez M, Kuper K, Al-Taie A, Kotb REM. Assessing the global economic burden of complicated urinary tract infections. Poster presented at the IDWeek 2024; October 18, 2024. Los Angeles, California.

Howard-Anderson JR, Brown M, Korn RE, Miller J, Norman Sutton K, Ruffin F, Thomas S, Obi EN, Sidduri N, Watanabe AH, Yucel E, Bosworth H, Boucher H, Collyar D, Doernberg SB, Oakes M, Reeve BB, Fowler VG, King H. Comparing patient and clinician perceptions of health-related quality of life in hospitalized patients with complicated urinary tract infections: a qualitative descriptive study. Poster presented at the IDWeek 2024; October 18, 2024. Los Angeles, CA.

La E, Sweeney C, Singer D, Davenport E, Calhoun S, Harmelink A. Factors associated with healthcare professionals' RSV older adult vaccination knowledge and practices during the first season of vaccine availability in the United States. Poster presented at the IDWeek 2024; October 17, 2024. Los Angeles, CA.

Carrico J, Talbird SE, Eiden A, Carias C, Huang M, Lang JC, Marshall GS, Bencina G. Direct impact of pediatric immunization on reduction in antibiotic prescribing in the United States. Poster presented at the IDWeek 2024; October 17, 2024. Los Angeles, CA.

Rider NL, Zichlin ML, Schick B, Berstein M, Fladhammer D, Schwab P, Gladiator A. Evaluating treatment experience during initiation of subcutaneous immunoglobulin replacement therapy at home using a custom interactive voice assistant. Poster presented at the 21st Biennial Meeting of European Society for Immunodeficiencies (ESID); October 16, 2024. Marseille, France.

Grace M, Wang K, Graham CN. Budget impact of injectafer (ferric carboxymaltose injection) for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity on a third-party US payer. Poster presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024; October 14, 2024. Las Vegas, NV.

Anderson SA, Bian B, Talbird SE, Stratton M, Maxwell R, Ferries R. Medical cost and healthcare resource utilization offset for zuranolone relative to SSRIs in the treatment of postpartum depression. Poster presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024; October 14, 2024. Las Vegas, NV.

Sauchelli S, Levy C, Gnanasakthy A, Doward L, Fitzgerald K. Inclusion of patient-reported outcome endpoints in the summary of product characteristics for non-oncology drugs approved by the European Medicines Agency (2018-2022). Poster presented at the ISOQOL 31st Annual Conference; October 13, 2024. Cologne, Germany.

Buck P, Sweeney C, Georgieva M, Kunzweiler C, Tossonian H, Boyle K, Chirila C, Crawford R, Wolowacz S, Pesch M. Family spillover impact of congenital CMV in the United States and Canada: study methodology. Poster presented at the European Congenital Cytomegalovirus Initiative (ECCI) 2024; October 9, 2024. Leiden, the Netherlands.

Buck P, Graham J, Grace M, Myers E, Diaz-Decaro J. Public health impact of vaccination strategies in 16-to-40-year-old females for the prevention of CMV and congenital CMV in the United States. Poster presented at the European Congenital Cytomegalovirus Initiative (ECCI) 2024; October 9, 2024. Leiden, The Netherlands. Previously presented at the European Society for Paediatric Infectious Diseases (ESPID) 2024.

Neumann ML, Ladner A, Allen JY, Kakani S, Rauen MH, Raghu V, Mercer DF. Assessing quality of life with pediatric intestinal failure: initial results from the application of a novel disease-specific questionnaire. Poster presented at the 13th International Pediatric Intestinal Failure and Rehabilitation Symposium (PIFRS) 2024; September 28, 2024. Pittsburgh, PA.

Kohli RK, Hawe E, Harold S, Simou E, Chrysos AE, Orfanos P. Utility scores in chronic spontaneous urticaria: a systematic literature review and statistical analysis. Poster presented at the European Academy of Dermatology & Venereology (EADV) Congress 2024; September 25, 2024. Amsterdam, Netherlands.

Mayer SE, Kawai A, Fuller CC, Agan AA, Rao S, Koram N, Calingaert B, Marshall J, Connolly JG, Moyneur E, Jamal-allial A, Brown J, Burk J, Chomistek A, Daniels K, Dea K, DeFor TA, Diessner B, Djibo DA, Ezzy S, Hawrusik R, Johannes CB, Kendrick K, Layton JB, Ma Q, Mai X, Mack M, Pawloski PA, Reynolds JS, Selvan M, Sharma V, Vetter J, McMahill-Walraven CN, Platt R, Gilsenan A. Interim utilization results from a post-approval safety study of Pfizer-BioNTech monovalent COVID-19 vaccine in the United States. Poster presented at the 2024 ISPE Annual Meeting; August 28, 2024. Berlin, Germany.

Cid Royo A, Choi J, Plana E, Garcia Esteban R, Pajouheshnia R, Ryan O. A flexible open-source analytic pipeline for self-controlled analysis of real world data. Poster presented at the 2024 ISPE Annual Meeting; August 28, 2024. Berlin, Germany.